Insights

Gathering insights about Springworks…

Similar companies to Springworks

Springworks Tech Stack

Springworks uses 8 technology products and services including Gravatar, CookieYes, MySQL, and more. Explore Springworks's tech stack below.

Gravatar
Audio, Video, Graphics
CookieYes
Cookie Compliance
MySQL
Database
Google Fonts API
Font Scripts
Next.js
Javascript Frameworks
Elementor
Page Builders
Webflow
Page Builders
Autoptimize
Web Platform Extensions

Media & News

SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
– Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and consistent safety profile –
Oct 21, 2025 | www.globenewswire.com
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and consistent safety profile Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and consistent safety profile
Oct 21, 2025 | www.globenewswire.com
European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
Aug 18, 2025 | www.globenewswire.com
European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
Aug 18, 2025 | www.globenewswire.com
Immunome: SpringWorks Buyout Informs The Potential Upside Here
Immunome's lead asset, varegacestat, shows promising efficacy in desmoid tumors, with phase 3 topline data expected by the end of 2025. IMNM holds Orphan Drug designations in the US and Europe, potentially enabling accelerated approval if phase 3 results are positive. Cash reserves of $143.9M and marketable securities of $124.2M provide runway into 2027, despite a high annualized cash burn.
Aug 11, 2025 | seekingalpha.com
European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms – – EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –
Jul 18, 2025 | www.globenewswire.com
European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms – – EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –
Jul 18, 2025 | www.globenewswire.com

Springworks's Email Address Formats

Springworks uses at least 2 format(s):

Springworks Email Formats	Example	Percentage
First@springrole.com	John@springrole.com	57%
First.Last@springrole.com	John.Doe@springrole.com	41%
Last@springrole.com	Doe@springrole.com	2%
First.Last@springworks.in	John.Doe@springworks.in	100%

Frequently Asked Questions

Where is Springworks's headquarters located?

Springworks's main headquarters is located at 1447 2nd Street, Santa Monica, CA 90401, IN. The company has employees across 3 continents, including AsiaNorth AmericaEurope.

What is Springworks's stock symbol?

Springworks is a publicly traded company; the company's stock symbol is SWTX.

What is Springworks's official website and social media links?

Springworks's official website is springworks.in and has social profiles on LinkedIn Crunchbase.

What is Springworks's NAICS code?

Springworks's NAICS code is 5415 - Computer Systems Design and Related Services.

How many employees does Springworks have currently?

As of October 2025, Springworks has approximately 334 employees across 3 continents, including AsiaNorth AmericaEurope. Key team members include Chief Executive Officer: J. P.Chief Executive Officer: K. C.Chief Operating Officer: A. S.. Explore Springworks's employee directory with LeadIQ.

What industry does Springworks belong to?

Springworks operates in the Technology, Information and Internet industry.

What technology does Springworks use?

Springworks's tech stack includes GravatarCookieYesMySQLGoogle Fonts APINext.jsElementorWebflowAutoptimize.

What is Springworks's email format?

Springworks's email format typically follows the pattern of First@springrole.com. Find more Springworks email formats with LeadIQ.

How much funding has Springworks raised to date?

As of October 2025, Springworks has raised $1.3M in funding. The last funding round occurred on May 14, 2018 for $1.3M.

When was Springworks founded?

Springworks was founded in 2014.

Springworks

Technology, Information and InternetIndia201-500 Employees

Springworks helps companies build a category-defining work culture. 

The product stack from Springworks includes: 
SpringVerify — B2B verification platform, 
EngageWith — an employee recognition and rewards platform that enriches company culture, and 

Springworks prides itself on being an organization focused on employee well-being and workplace culture leading to the 200+ employee strength company being rated 4.6 on Glassdoor fully remote.

Company Overview

Headquarters: 1447 2nd Street, Santa Monica, CA 90401, IN
Website: springworks.in
Stock Symbol: SWTX
NAICS Code: 5415 - Computer Systems Design and Related Services
Founded: 2014
Employees: 201-500

Media & News

Funding & Financials

$1.3M
Springworks has raised a total of $1.3M of funding over 2 rounds. Their latest funding round was raised on May 14, 2018 in the amount of $1.3M.
$25M$50M
Springworks's revenue is estimated to be in the range of $25M$50M

Funding & Financials

$1.3M
Springworks has raised a total of $1.3M of funding over 2 rounds. Their latest funding round was raised on May 14, 2018 in the amount of $1.3M.
$25M$50M
Springworks's revenue is estimated to be in the range of $25M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Springworks

Techwave

TechSpring

TechWorks

Codespring

Springworks Tech Stack

Media & News

SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology

SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology

European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors

European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors

Immunome: SpringWorks Buyout Informs The Potential Upside Here

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

Springworks's Email Address Formats

Frequently Asked Questions

Where is Springworks's headquarters located?

What is Springworks's stock symbol?

What is Springworks's official website and social media links?

What is Springworks's NAICS code?

How many employees does Springworks have currently?

What industry does Springworks belong to?

What technology does Springworks use?

What is Springworks's email format?

How much funding has Springworks raised to date?

When was Springworks founded?

Springworks

Company Overview

Media & News

SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology

SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology

European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?